Emanuele marra Marra

Dr. Emanuele marra Marra

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2020 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
GSGiovanni Salvatori
Giovanni Salvatori
LLLaura Luberto
Laura Luberto
MMMariano Maffei
Mariano Maffei
LALuigi Aurisicchio
Luigi Aurisicchio
GRGiuseppe Roscilli
Giuseppe Roscilli
EMEmanuele marra Marra
Emanuele marra Marra
COVID-19 has rapidly spread all over the world, progressing into a pandemic. This situation has urgently impelled many companies and public research institutes to concentrate their efforts on research for effective therapeutics. Here, we outline the strategies and targets currently adopted in developing a vaccine against SARS-CoV-2. Based on previous evidence and experience with SARS and MERS, the primary focus has been the Spike protein, considered as the ideal target for COVID-19 immunotherapies.

5 February 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
TMTomas Di Mambro
Tomas Di Mambro
IGIlaria Guerriero
Ilaria Guerriero
LALuigi Aurisicchio
Luigi Aurisicchio
Mauro MagnaniMauro Magnani
Mauro Magnani
EMEmanuele marra Marra
Emanuele marra Marra
Fungal infections have aroused much interest over the last years because of their involvement in several human diseases. Immunocompromission due to transplant-related therapies and malignant cancer treatments are risk factors for invasive fungal infections, but also aggressive surgery, broad-spectrum antibiotics and prosthetic devices are frequently associated with infectious diseases. Current therapy is based on the administration of antifungal drugs, but the occurrence of resistant strains to the most common molecules has become a serious health-care problem. New antifungal agents are urgently needed and it is essential to identify fungal molecular targets that could offer alternatives for development of treatments. The fungal cell wall and plasma membrane are the most important structures that offer putative new targets which can be modulated in order to fight microbial infections. The development of monoclonal antibodies against new targets is a valid therapeutic strategy, both to solve resistance problems and to support the immune response, especially in immunocompromised hosts. In this review, we summarize currently used antifungal agents and propose novel therapeutic approaches, including new fungal molecular targets to be considered for drug development.

1 April 2012 in Cell Cycle
Verified
Journal Article
Closed access
PDF file
FBFrancesca Belleudi
Francesca Belleudi
EMEmanuele marra Marra
Emanuele marra Marra
FMFrancesca Mazzetta
Francesca Mazzetta
LFLuigi Fattore
Luigi Fattore
MGMaria Rosaria Giovagnoli
Maria Rosaria Giovagnoli
Gennaro CilibertoGennaro Ciliberto
Gennaro Ciliberto
Members of the ErbB receptor family are targets of a growing numbers of small molecules and monoclonal antibodies inhibitors currently under development for the treatment of cancer. Although historical efforts have been directed against ErbB1 (EGFR) and ErbB2 (HER2/neu), emerging evidences have pointed to ErbB3 as a key node in the activation of proliferation/survival pathways from the ErbB receptor family and have fueled enthusiasm toward the clinical development of anti-ErbB3 agents. In this study, we have evaluated the potential therapeutic efficacy of a set of three recently generated anti-human ErbB3 monoclonals, A2, A3 and A4, in human primary melanoma cells. We show that in melanoma cells expressing ErbB1, ErbB3 and ErbB4 but not ErbB2 receptor ligands activate the PI3K/AKT pathway, and this leads to increased cell proliferation and migration. While antibodies A3 and A4 are able to potently inhibit ligand-induced signaling, proliferation and migration, antibody A2 is unable to exert this effect. In attempt to understand the mechanism of action and the basis of this different behavior, we demonstrate, through a series of combined approaches, that antibody efficacy strongly correlates with antibody-induced receptor internalization, degradation and inhibition of receptor recycling to the cell surface. Finally, fine epitope mapping studies through a peptide array show that inhibiting vs. non-inhibiting antibodies have a dramatically different mode of binding to the to the receptor extracellular domain. Our study confirms the key role of ErbB3 and points to exploitation of novel combination therapies for treatment of malignant melanoma.

2 December 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
MMMariano Maffei
Mariano Maffei
Linda Celeste MontemiglioLinda Celeste Montemiglio
Linda Celeste Montemiglio
GVGrazia Vitagliano
Grazia Vitagliano
LFLuigi Fedele
Luigi Fedele
SSShaila Sellathurai
Shaila Sellathurai
EMEmanuele marra Marra
Emanuele marra Marra
COVID-19 is a highly infectious disease caused by a newly emerged coronavirus (SARS-CoV-2) that has rapidly progressed into a pandemic. This unprecedent emergency has stressed the significance of developing effective therapeutics to fight the current and future outbreaks. The receptor-binding domain (RBD) of the SARS-CoV-2 surface Spike protein is the main target for vaccines and represents a helpful “tool” to produce neutralizing antibodies or diagnostic kits. In this work, we provide a detailed characterization of the native RBD produced in three major model systems: Escherichia coli, insect and HEK-293 cells. Circular dichroism, gel filtration chromatography and thermal denaturation experiments indicated that recombinant SARS-CoV-2 RBD proteins are stable and correctly folded. In addition, their functionality and receptor-binding ability were further evaluated through ELISA, flow cytometry assays and bio-layer interferometry.

1 January 2022 in International Journal of Dentistry
Verified
Journal Article
Open access
PDF file
GGGiuseppe Giannini
Giuseppe Giannini
IRIrene Ragusa
Irene Ragusa
GNGiulia Nerina Nardone
Giulia Nerina Nardone
SSSara Soldi
Sara Soldi
MEMarina Elli
Marina Elli
EPEmilio Merlo Pich
Emilio Merlo Pich
Objective. Periodontitis is a common disorder that leads to the loss of both tooth and personal well‐being, contributing to worsen the risk for metabolic and cardiovascular diseases. Recently, probiotics, characterized by rapid oral dispersion, have been topically used. Here, we present data of a mucoadhesive gel containing probiotics, capable of ensuring a slow release of bacteria to prevent and treat periodontitis. Methods. An original mucoadhesive gel (AL0005) that is anhydrous and of food grade, loaded with the blend of lactobacilli and plants’ dry extracts, has been assayed. Results. The release kinetics of the bacterial mixture in different experimental models in vitro, including simulated saliva or physiological solutions, showed a significant and stable release for 5–8 hours. In one in vivo study of a mouse model of periodontitis, a locally applied mucoadhesive gel enriched with probiotic strains improved significantly the tissue pathology when compared with vehicle‐exposed mice. Conclusions. Together, the results suggest that this mucoadhesive gel can be useful in the normalization of the gum bacterial flora and improvement of the tissue pathology of gum disorders.

24 March 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
LVlore vesci
lore vesci
GTGrazia Raffaella Tundo
Grazia Raffaella Tundo
SSSara Soldi
Sara Soldi
SGSerena Galletti
Serena Galletti
DSDaniela Stoppoloni
Daniela Stoppoloni
SMStefano Marini
Stefano Marini
Crohn’s and ulcerative colitis are common conditions associated with inflammatory bowel disease as well as intestinal flora and epithelial barrier dysfunction. A novel fermented Lactobacillus brevis (AL0035) herein assayed in a trinitro benzene sulfonic acid (TNBS)-induced colitis mice model after oral administration significantly counteracted the body weight loss and improves the disease activity index and histological injury scores. AL0035 significantly decreased the mRNA and protein expression of different pro-inflammatory cytokines (TNFalpha, IL-1beta, IL-6, IL-12, IFN-gamma) and enhanced the expression of IL-10. In addition, the probiotic promoted the expression of tight junction proteins, such as ZO-1, keeping the intestinal mucosal barrier function to attenuate colitis symptoms in mice. Markers of inflammation cascade such as myeloperoxidase (MPO) and PPAR-gamma measured in the colon were also modified by AL0035 treatment. AL0035 was also able to reduce different lymphocyte markers’ infiltration in the colon (GATA-3, T-Bet, NK1.1) and monocyte chemoattractant protein-1 (MCP-1/CCL2), a key chemokine involved in the migration and infiltration of monocytes/macrophages in the immunological surveillance of tissues and inflammation. In colonic microbiota profile analysis through 16S rRNA sequencing, AL0035 increased the microbial diversity depleted by TNBS administration and the relative abundance of the Lactobacillaceae and Lachnospiraceae families, whereas it decreased the abundance of Proteobacteria. Altogether, these data indicated that AL0035 could lower the severity of colitis induced by TNBS by regulating inflammatory cytokines, increasing the expression of tight junction proteins and modulating intestinal microbiota, thus preventing tissue damage induced by colitis.